Per reporter: Chen Xing Per editor: Wen Duo
Clover (02197.hk), which holds the new crown recombinant protein vaccine, was officially listed on the Hong Kong Stock Exchange on the 5th. As a star stock blessed by institutional shareholders such as Hillhouse Capital and Temasek, Clover once fell by more than 5% on the first day of listing. As of the close of the day, Clover was trading at HK$12.98 per share, down 2.99%, below the offering price of HK$13.38.
The reason for gaining the favor of star capital, clover's "attraction" is mainly in its combination adjuvant use of recombinant protein new crown vaccine SCB-2019 (CPG 1018/aluminum adjuvant). According to the clover prospectus, the COVID-19 vaccine candidate is expected to be conditionally approved between the fourth quarter of 2021 and the middle of 2022.
But in fact, globally, there are 14 candidate vaccines for the recombinant protein subunit class to which it belongs. From a domestic point of view alone, Zhifei Bio's recombinant protein new crown vaccine has also been approved for emergency use.
Daily economic news